PAVmed (PAVM) Q4 2025 earnings summary

Executive summary

• Completed major restructuring and recapitalization in February, eliminating toxic convertible securities and strengthening the capital structure with $30M Series D preferred stock and $15M senior secured note financing, resulting in a clean balance sheet and extended cash runway.

• Now positioned as a high-growth, diversified life sciences company with independently financed subsidiaries under a shared services model.

• Core businesses include Lucid (diagnostics), Veris (digital health/cancer care), and a relaunching MedTech portfolio under new leadership, including licensed endoscopic imaging technology from Duke University.

• Lucid Diagnostics expanded access to EsoGuard, securing a VA contract and reporting positive real-world data from nearly 12,000 at-risk patients.

• Veris Health advanced commercial integration with OSU, fully integrating with the hospital's EHR and progressing its implantable physiological monitor toward late 2026 FDA submission.

Financial highlights

• Q4 2025 revenue was $1.5M from EsoGuard, with 3,664 tests processed, and total Q4 revenue and management fee income reached $4.38M, up $1.22M year-over-year.

• Full-year 2025 revenue was $13.85M, down $0.45M from 2024.

• Q4 2025 GAAP net loss was $2.8M, with a non-GAAP loss of $0.94M and EBITDA of $(1.96)M.

• Cash and cash equivalents at year-end 2025 were $1.54M, up $0.35M from prior year.

• Total assets post-financing exceed $100M, with $15M in long-term debt.

Outlook and guidance

• Positioned for high growth as a diversified commercial life sciences company, with plans to accelerate execution of an expanded strategic plan, including relaunching the MedTech portfolio and expanding Veris's commercial reach after FDA clearance of the implantable device.

• Veris Health targets late 2026 FDA 510(k) submission for its implantable physiological monitor.

• Lucid Diagnostics approaches transformative Medicare coverage for EsoGuard.

• Plans to integrate AI-based clinical decision tools into Veris and expand clinical support services.

• Anticipates leveraging commercial success at OSU to additional cancer centers and PE-backed oncology networks.